Diligence memo · auto-generated · as of July 2, 2026
Spiral Therapeutics Inc
Spiral Therapeutics Inc looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Spiral Therapeutics Inc operates in Pharma, based in SOUTH SAN FRANCISCO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Spiral Therapeutics Inc has raised $19M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $11M on 2022-10-18.
Most recent recorded round closed around 2022-10-18.
Valuation (modeled)modeled
Provath models Spiral Therapeutics Inc at approximately $121M (range $12M–$386M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.76× the median modeled value of Series A Pharma companies in 2022–2024 (24 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 23 months.
Last raise 3.7 yr ago; this sector typically re-raises about every 16 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 8.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 76% of Pharma peers (310 compared).
Modeled value ranks above 69% of those peers.
Closest niche peers: Carmine Therapeutics, Inc., Triomics, Inc., Convelo Therapeutics, Inc., ADvantage Therapeutics, Inc., Galaxy Therapeutics Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.